Allergan (AGN +1.5%) continues to battle back from yesterdays's 6% selloff after missing Q1 estimates, helped by positive comments out of Susquehanna this morning. The firm says AGN posted a good quarter, but wasn't surprised by the selloff and believe it's been overdone. Susquehanna says AGN adequately explained its shortcomings and expects to see growth accelerate through the remainder of the year. Worth noting: Jefferies says valuation is still rich on a relative basis, trading at around 20x estimates, versus its peers at 12x.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Nasdaq.com (Tue, 9:00AM)
at CNBC.com (Feb 18, 2015)
at CNBC.com (Feb 10, 2015)
at CNBC.com (Jan 26, 2015)
at Nasdaq.com (Jan 21, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs